Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2003

01-12-2003 | Case Report

The Bisphosphonate Zoledronic Acid Induces Cytotoxicity in Human Myeloma Cell Lines with Enhancing Effects of Dexamethasone and Thalidomide

Authors: A. Ugur Ural, M. Ilker Yilmaz, Ferit Avcu, Aysel Pekel, Murat Zerman, Oral Nevruz, Ali Sengul, Atilla Yalcin

Published in: International Journal of Hematology | Issue 5/2003

Login to get access
Metadata
Title
The Bisphosphonate Zoledronic Acid Induces Cytotoxicity in Human Myeloma Cell Lines with Enhancing Effects of Dexamethasone and Thalidomide
Authors
A. Ugur Ural
M. Ilker Yilmaz
Ferit Avcu
Aysel Pekel
Murat Zerman
Oral Nevruz
Ali Sengul
Atilla Yalcin
Publication date
01-12-2003
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2003
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02983818

Other articles of this Issue 5/2003

International Journal of Hematology 5/2003 Go to the issue

OriginalPaper

Gene Expression Profiling in Childhood Acute Leukemia: Progress and Perspectives

Meeting Report

Third International Symposium on Myelodysplastic Syndromes in Childhood

OriginalPaper

Molecular Pharmacodynamics in Childhood Leukemia

Case Report

Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia A

OriginalPaper

The Signaling Pathways of Erythropoietin and Interferon-γ Differ in Preventing the Apoptosis of Mature Erythroid Progenitor Cells

Case Report

Autologous Hematopoietic Stem Cell Transplantation for 3 Patients with Severe Juvenile Rheumatoid Arthritis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits